Skip to main content
. 2008 Mar 5;28(10):2435–2446. doi: 10.1523/JNEUROSCI.4402-07.2008

Table 1.

Comparison of SPN properties in control conditions and in the presence of SCH-23390, sulpiride, or d-AP-5

Control (n = 74) SCH-23390 (n = 16) Sulpiride (n = 14) d-AP-5 (n = 12)
RMP (mV) −83.5 ± 0.4 −83.4 ± 1.3 −82.4 ± 0.7 −85.4 ± 0.7
Input resistance (MΩ) 139 ± 10 137 ± 9 164 ± 22 138 ± 15
AP amplitude (mV) 74.8 ± 1.3 76.8 ± 2.5 74.5 ± 2.7 77.3 ± 3.0
AP threshold (mV) −33.9 ± 0.8 −35.5 ± 1.4 −33.3 ± 2.0 −35.9 ± 1.8
AP half-width (ms) 1.04 ± 0.02 1.05 ± 0.03 1.06 ± 0.11 1.12 ± 0.04
AP delay (ms) 147 ± 5 155 ± 8 136 ± 8 138 ± 11
AHP amplitude (mV) −12.0 ± 0.3 −10.4 ± 0.8 −12.4 ± 0.8 −10.5 ± 0.6
AHP time to peak (ms) 14.5 ± 1.1 13.7 ± 1.8 12.8 ± 2.1 14.5 ± 1.5
I inj. threshold to elicit AP (pA) 265 ± 16 240 ± 26 250 ± 23 266 ± 31
# APs at threshold 1.2 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 1.2 ± 0.1
# APs 50 pA above threshold 3.1 ± 0.2 3.3 ± 0.3 2.9 ± 0.8 3.0 ± 0.3
EPSP amplitude (mV) 4.80 ± 0.29 4.68 ± 0.60 4.02 ± 0.29 4.09 ± 0.56
EPSP 20–80% RT (ms) 2.10 ± 0.13 2.33 ± 0.12 2.51 ± 0.23 2.39 ± 0.17
EPSP latency (ms) 2.58 ± 0.10 2.10 ± 0.17 2.93 ± 0.18 2.71 ± 0.15
EPSP half-width (ms) 15.3 ± 0.7 18.5 ± 1.0* 19.3 ± 1.6* 14.8 ± 0.4
PPR 1.27 ± 0.07 1.06 ± 0.12 0.91 ± 0.08* 1.15 ± 0.12

Data are mean ± SEM (*p < 0.05). Time-to-peak and amplitude of afterhyperpolarization (AHP) were measured from AP threshold. I inj., Current injection required to elicit APs; #, number of obtained APs; RT, rise time. AP delay was determined with respect to onset of current injection.

HHS Vulnerability Disclosure